Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing medicines for the management of prostate cancer. The Company operates in two segments: Commercial and Research, and Development. The Commercial segment consists of FC2. The Research and Development segment consists of multiple drug products under clinical development for oncology and urology. The Company's prostate cancer pipeline includes VERU-111, VERU-100 and Zuclomiphene Citrate. VERU-111 is an oral chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules. VERU-100 is a peptide formulation designed to address the limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. The Company's commercial products include FC2 Female Condom/FC2 Internal Condom (FC2), a product for the protection against unintended pregnancy and sexually transmitted infections.